443 related articles for article (PubMed ID: 23417499)
1. 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type.
Balogova S; Talbot JN; Nataf V; Michaud L; Huchet V; Kerrou K; Montravers F
Eur J Nucl Med Mol Imaging; 2013 Jun; 40(6):943-66. PubMed ID: 23417499
[TBL] [Abstract][Full Text] [Related]
2. Role of (18) F-FDOPA PET/CT imaging in endocrinology.
Santhanam P; Taïeb D
Clin Endocrinol (Oxf); 2014 Dec; 81(6):789-98. PubMed ID: 25056984
[TBL] [Abstract][Full Text] [Related]
3. The Added Diagnostic Value of
Addeo P; Poncet G; Goichot B; Leclerc L; Brigand C; Mutter D; Romain B; Namer IJ; Bachellier P; Imperiale A
J Gastrointest Surg; 2018 Apr; 22(4):722-730. PubMed ID: 29235002
[TBL] [Abstract][Full Text] [Related]
4. 18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation.
Imperiale A; Rust E; Gabriel S; Detour J; Goichot B; Duclos B; Kurtz JE; Bachellier P; Namer IJ; Taïeb D
J Nucl Med; 2014 Mar; 55(3):367-72. PubMed ID: 24343986
[TBL] [Abstract][Full Text] [Related]
5. 6-[F-18]fluoro-L-DOPA positron emission tomography in the imaging of Merkel cell carcinoma: preliminary report of three cases with 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography or pentetreotide-(111In) SPECT data.
Talbot JN; Kerrou K; Missoum F; Grahek D; Aide N; Lumbroso J; Montravers F
Mol Imaging Biol; 2005; 7(4):257-61. PubMed ID: 16082495
[TBL] [Abstract][Full Text] [Related]
6. Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy.
King KS; Chen CC; Alexopoulos DK; Whatley MA; Reynolds JC; Patronas N; Ling A; Adams KT; Xekouki P; Lando H; Stratakis CA; Pacak K
J Clin Endocrinol Metab; 2011 Sep; 96(9):2779-85. PubMed ID: 21752889
[TBL] [Abstract][Full Text] [Related]
7. Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET.
Becherer A; Szabó M; Karanikas G; Wunderbaldinger P; Angelberger P; Raderer M; Kurtaran A; Dudczak R; Kletter K
J Nucl Med; 2004 Jul; 45(7):1161-7. PubMed ID: 15235062
[TBL] [Abstract][Full Text] [Related]
8. What is currently the best radiopharmaceutical for the hybrid PET/CT detection of recurrent medullary thyroid carcinoma?
Slavikova K; Montravers F; Treglia G; Kunikowska J; Kaliska L; Vereb M; Talbot JN; Balogova S
Curr Radiopharm; 2013 Jun; 6(2):96-105. PubMed ID: 23745775
[TBL] [Abstract][Full Text] [Related]
9. Imaging of neuroendocrine tumors.
Rufini V; Calcagni ML; Baum RP
Semin Nucl Med; 2006 Jul; 36(3):228-47. PubMed ID: 16762613
[TBL] [Abstract][Full Text] [Related]
10. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.
Binderup T; Knigge U; Loft A; Mortensen J; Pfeifer A; Federspiel B; Hansen CP; Højgaard L; Kjaer A
J Nucl Med; 2010 May; 51(5):704-12. PubMed ID: 20395333
[TBL] [Abstract][Full Text] [Related]
11. Novel PET tracers: added value for endocrine disorders.
Bergeret S; Charbit J; Ansquer C; Bera G; Chanson P; Lussey-Lepoutre C
Endocrine; 2019 Apr; 64(1):14-30. PubMed ID: 30875057
[TBL] [Abstract][Full Text] [Related]
12. 18F-fluorodihydroxyphenylalanine in the diagnosis of neuroendocrine tumors.
Minn H; Kemppainen J; Kauhanen S; Forsback S; Seppänen M
PET Clin; 2014 Jan; 9(1):27-36. PubMed ID: 25029931
[TBL] [Abstract][Full Text] [Related]
13. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?
Montravers F; Grahek D; Kerrou K; Ruszniewski P; de Beco V; Aide N; Gutman F; Grangé JD; Lotz JP; Talbot JN
J Nucl Med; 2006 Sep; 47(9):1455-62. PubMed ID: 16954553
[TBL] [Abstract][Full Text] [Related]
14. Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours.
Van Binnebeek S; Vanbilloen B; Baete K; Terwinghe C; Koole M; Mottaghy FM; Clement PM; Mortelmans L; Bogaerts K; Haustermans K; Nackaerts K; Van Cutsem E; Verslype C; Verbruggen A; Deroose CM
Eur Radiol; 2016 Mar; 26(3):900-9. PubMed ID: 26162577
[TBL] [Abstract][Full Text] [Related]
15. Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy.
Hicks RJ
Cancer Imaging; 2010 Oct; 10 Spec no A(1A):S83-91. PubMed ID: 20880795
[TBL] [Abstract][Full Text] [Related]
16.
Kroiss AS; Uprimny C; Shulkin BL; Gruber L; Frech A; Url C; Riechelmann H; Sprinzl GM; Thomé C; Treglia G; Kjaer A; Fraedrich G; Virgolini IJ
Nucl Med Biol; 2019 Apr; 71():47-53. PubMed ID: 31152973
[TBL] [Abstract][Full Text] [Related]
17. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours.
Adams S; Baum R; Rink T; Schumm-Dräger PM; Usadel KH; Hör G
Eur J Nucl Med; 1998 Jan; 25(1):79-83. PubMed ID: 9396878
[TBL] [Abstract][Full Text] [Related]
18. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.
Fottner C; Helisch A; Anlauf M; Rossmann H; Musholt TJ; Kreft A; Schadmand-Fischer S; Bartenstein P; Lackner KJ; Klöppel G; Schreckenberger M; Weber MM
J Clin Endocrinol Metab; 2010 Jun; 95(6):2800-10. PubMed ID: 20371665
[TBL] [Abstract][Full Text] [Related]
19. Intraindividual comparison of
Ouvrard E; Chevalier E; Addeo P; Sahakian N; Detour J; Goichot B; Bachellier P; Karcher G; Taïeb D; Imperiale A
Clin Endocrinol (Oxf); 2021 Jan; 94(1):66-73. PubMed ID: 32790887
[TBL] [Abstract][Full Text] [Related]
20. Nuclear medicine imaging of neuroendocrine tumours.
Bombardieri E; Maccauro M; De Deckere E; Savelli G; Chiti A
Ann Oncol; 2001; 12 Suppl 2():S51-61. PubMed ID: 11762353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
